

Haspin Kinase

Haspin is a protein kinase that regulates chromosome and spindle function during mitosis and meiosis. Haspin expression is detected in fetal liver, skin, kidney, small intestine and in all proliferating cells. Haspin phosphorylates H3 thr3 (H3T3ph) in human cell lines and depletion of Haspin by RNA interference reveals that Haspin is required for H3 thr3 phosphorylation in mitotic cells. Phosphorylation of H3T3ph by Haspin is necessary for chromosomal passenger complex (CPC) accumulation at centromeres. H3T3ph then positions the CPC at centromeres to regulate selected targets of Aurora B during mitosis.

Haspin Kinase Inhibitors

CHR-6494	Cat. No. : HY-15217	CHR-6494 TFA	Cat. No. : HY-110350
CHR-6494 is a potent inhibitor of haspin, with an IC ₅₀ of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer. Purity: 98.70% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg		CHR-6494 TFA is a potent inhibitor of haspin , with an IC ₅₀ of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer. Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg	
Haspin-IN-1	Cat. No.: HY-146586	Haspin-IN-2	Cat. No.: HY-146587
Haspin-IN-1 (compound 2a) is a haspin inhibitor with an IC_{50} of 119 nM. Haspin-IN-1 also inbibits CLK1 and DYRK1A with IC_{50} s of 221 nM and 916.3 nM, respectively.	°O. _N +O N N N	Haspin-IN-2 (compound 4) is a potent and selective haspin inhibitor with an IC_{50} of 50 nM. Haspin-IN-1 also inbibits CLK1 and DYRK1A with IC_{50} s of 445 nM and 917 nM, respectively.	
Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg		Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg	
Haspin-IN-3		LDN-192960	
	Cat. No.: HY-146636		Cat. No.: HY-13455
Haspin-IN-3 (compound 8l) is a potent haspin inhibitor with IC_{50} of 14 nM. Haspin-IN-3 has anticancer effects.		LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC ₅₀ s of 10 nM and 48 nM, respectively.	NH2 S
Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg		Purity:99.56%Clinical Data:No Development ReportedSize:10 mM × 1 mL, 5 mg, 10 mg	N N N
LDN-192960 hydrochloride		LDN-209929 dihydrochloride	
	Cat. No.: HY-13455A		Cat. No.: HY-110320
LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC ₅₀ s of 10 nM and 48 nM, respectively.	S S S S S S S S S S S S S S S S S S S	LDN-209929 dihydrochloride is a potent and selective haspin kinase inhibitor (IC_{50} =55 nM) with180-fold selectivity verses DYRK2 (IC_{50} =9.9 μ M). LDN-209929 is a optimized analogue of LDN-192960 (HY-13455).	O CI
Purity: ≥98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg	~~~N^~~	Purity: ≥98.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg	H-CI H-CI